Proliferation suppression by pitavastatin and atorvastatin was
investigated in the human cholangiocarcinoma cell lines
HuCCT1 and YSCCC while changes in the cell cycle and
intracellular signals were examined by FACS and Western
blotting, respectively. Additive proliferation suppression by
statins and pre-existing anticancer drugs was also investigated.
Given the poor prognosis for cholangiocarcinoma, new and
effective treatments are urgently needed. HMG-CoA reductase
inhibitors (statins) reportedly exert anticancer effects in a variety
of diseases, but there have been no reports of these effects in
HuCCT1 and YSCCC cell proliferation was dramatically
suppressed by incubation with statins for 72 h or longer. Cell cycle analysis revealed a reduction in the G2M fraction
and an increase in the sub-G1 fraction in statin-treated cells, while Western blotting showed increased levels of
cleaved caspase-3 and a reduction in p-ERK. Furthermore, statins in combination with gemcitabine, cisplatin and 5-FU
showed additive proliferation suppression.
Int J Oncol. 2011 Sep; 39(3): 561-8.
Created ： 2012/04/24 15:58 Modified ： 2012/07/31 16:29